Pharmaceutical

Immune Thrombocytopenia by NovelMed Therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Jul 1, 2023 - 20:00
Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).
Read the original article

Tags:

Previous Article

SNK-396 by Synerk for Lipid Disorders: Likelihood of Approval

Next Article

Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemol...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

We wish we’d written that: STAT staffers share their favorite stories of 2023

We wish we’d written that: STAT staffers share their fa...

Dec 29, 2023

Panbela obtains rights to develop and commercialise Flynpovi to treat FAP

Panbela obtains rights to develop and commercialise Fly...

Apr 12, 2023

STAT+: FDA approves new treatment from Biogen for rare form of ALS

STAT+: FDA approves new treatment from Biogen for rare ...

Apr 25, 2023